Servier completes the acquisition of Day One Biopharmaceuticals
Acquisition expands Servier's position in oncology with tovorafenib marketed as OJEMDATM in the…
Servier and Day One Biopharmaceuticals announce acquisition to expand Servier’s rare oncology portfolio
Acquisition positions Servier as a leader in pediatric low-grade glioma and expands…
Servier delivers solid performance in 2024/25 and confirms its forecasts for 2030
Servier reported Group revenues of €6.9 billion for 2024/25, up 16.2% from…
Servier acquires potential treatment for Fragile X syndrome, the most common genetic cause of autism spectrum disorder
Servier acquires KER-0193, a potential treatment for Fragile X syndrome, developed by…
